Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 4, 2002, Pages 1067-1072

  Harrigan, P R ^a   Miller, M D ^a   McKenna, P ^a   Brumme, Z L ^a   Larder, B A ^a  

^a Visible Genetics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ARTICLE; ASSAY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LINEAR REGRESSION ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENETICS;

ADENINE; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0036203532     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.4.1067-1072.2002     Document Type: Article

References (20)

1. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults
2. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
3. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates
4. Worldwide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing
5. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
6. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples
7. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: In vitro analyses
8. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9(2-phosphonylmethoxypropyl)adenine in mice
9. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA
10. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques
11. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
12. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
13. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains
14. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonomethoxypropyl)adenine
15. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
16. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy in chronic SIV infection in macaques
17. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
18. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
19. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection
20. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA